Please use this identifier to cite or link to this item:
http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2325
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bayramoglu, Adil | - |
dc.contributor.author | Dereli, Seckin | - |
dc.contributor.author | Kaya, Ahmet | - |
dc.date.accessioned | 2022-08-17T05:33:22Z | - |
dc.date.available | 2022-08-17T05:33:22Z | - |
dc.date.issued | 2020 | - |
dc.identifier.uri | http://doi.org/10.2459/JCM.0000000000000895 | - |
dc.identifier.uri | http://earsiv.odu.edu.tr:8080/xmlui/handle/11489/2325 | - |
dc.description.abstract | Background Malnutrition commonly occurs in patients with heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan, which is an AT1 neprilysin inhibitor, has been shown to reduce mortality and hospitalization in patients with HFrEF. However, its effects on nutritional status remain unclear. Methods Sacubitril/valsartan was initiated in 164 symptomatic patients with HFrEF receiving an optimal medical treatment with angiotensin inhibition (mean age: 63 +/- 20 years; 120 males, 60% ischemic cause). The New York Heart Association (NYHA) functional class and nutritional statuses of the patients were evaluated at the switching to AT1 neprilysin inhibitor and at the 6th-month follow-up of the maximum sacubitril/valsartan dose using the geriatric nutritional risk index (GNRI), controlling nutritional status (CONUT) score, prognostic nutritional index (PNI), and prealbumin. Results After the sacubutril/valsartan treatment, a significant reduction in the number (%) of malnourished patients was observed according to CONUT (before 47% vs. after 7%,P < 0.001), GNRI (before 39% vs. after 19%,P < 0.001), PNI scores (before 36% vs. after 12%,P = 0.002), and prealbumin (before 41% vs. after 12%,P < 0.001). Also significant changes were observed at the baseline and follow-up in the mean scores of the three different nutritional indexes and prealbumin levels [CONUT: 2.68 +/- 2.5, 1.02 +/- 1.0 (P < 0.001); GNRI: 97.1 +/- 9.7, 101.2 +/- 5.9 (P < 0.001); PNI: 38.8 +/- 4.8, 41.6 +/- 3.7 (P < 0.001); prealbumin: 14.6 +/- 6.9 mg/dl, 17.1 +/- 5.2 mg/dl (P < 0.001)]. Overall, the patients exhibited a significant functional improvement following the initiation of sacubitril/valsartan: 23% of the patients improved by two NYHA classes, 48% improved by one NYHA class, and 39% remained stable. Conclusion In patients with HFrEF, the switch from angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy to sacubitril/valsartan resulted in a significant improvement in both nutritional and functional statuses. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS, TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA | en_US |
dc.relation.isversionof | 10.2459/JCM.0000000000000895 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | heart failure; malnutrition; prealbumin; sacubitril; valsartan | en_US |
dc.subject | RECEPTOR-NEPRILYSIN INHIBITOR; LCZ696 SACUBITRIL/VALSARTAN; CARDIAC CACHEXIA; SYSTEM; INDEX; TRANSTHYRETIN; INFLAMMATION; PREALBUMIN; MECHANISMS; ENALAPRIL | en_US |
dc.title | Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction | en_US |
dc.type | article | en_US |
dc.relation.journal | JOURNAL OF CARDIOVASCULAR MEDICINE | en_US |
dc.contributor.department | Ordu Üniversitesi | en_US |
dc.contributor.authorID | 0000-0001-9845-7938 | en_US |
dc.contributor.authorID | 0000-0002-6523-9130 | en_US |
dc.contributor.authorID | 0000-0003-0090-3835 | en_US |
dc.identifier.volume | 21 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.startpage | 13 | en_US |
dc.identifier.endpage | 20 | en_US |
Appears in Collections: | Dahili Tıp Bilimleri |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.